Sunitinib (Sutent) is a targeted therapy used to treat renal cell carcinoma in the kidney, gastrointestinal stromal tumours (GISTs) and pancreatic neuroendocrine tumours. It may be used in research trials for other cancers too. It works by blocking (inhibiting)...
There are many questions that kidney cancer patients and their families may have. Kidney Cancer UK have collated a list of the most frequently asked questions and their answers.
CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma (RCC) report less decline in health-related quality of life (HRQoL) during treatment than those given...
A special blog for Kidney Cancer Awareness Week 2023 by Richard Jetten I was 41 and running our own Spanish Tapas restaurant when one morning I noticed my wee had turned red, it looked just like Cherryade! Initially I dismissed this as a bad bottle of red wine from...
Kidney Cancer UK have collated information about the current drug based treatment options.
This group of pharmaceutical medicines target molecular pathways within the cancer cells. They act to reduce the cancer cells ability to grow and supply themselves with a blood supply. Cancer needs a good blood supply to bring food and oxygen and remove waste...
Studied in combination with Opdivo, Cabometyx saw RCC patients surviving 11 months longer than Sunitinib patients reports clinicaltrials.com. Five-year results from a trial examining Exelixis’ Cabometyx as a therapy for previously untreated advanced renal cell...
There are many terms associated with kidney cancer. Kidney Cancer UK has collated a comprehensive glossary of terms to help patients, carers and health professionals find the information they need.
This group of pharmaceutical medicines target molecular pathways within the cancer cells. They act to reduce the cancer cells ability to grow and supply themselves with a blood supply. Cancer needs a good blood supply to bring food and oxygen and remove waste...
The drug duo Kisplyx plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, extended follow-up of the CLEAR trial showed. Kisplyx (lenvatinib) plus Keytruda (pembrolizumab) improved outcomes in patients with advanced renal cell...
Kidney Cancer UK have provided a collection of informative videos about various aspects of kidney cancer treatment, research and other related subjects.
